We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Federal Circuit Rules For Shwarz Pharma In Suit Over Univasc Patent

Law360 (February 1, 2004, 12:00 AM EST) -- The U.S. Court of Appeals for the Federal Circuit has vacated a lower court’s decision that supported Israeli generics maker Teva's right to sell a generic form of Schwarz Pharma’s hypertension drug Univasc.

The U.S. District Court for the District of New Jersey had found that Teva's product, Moexipril HCl Tablets,would not infringe U.S. Patent No. 4,743,450, asserted by Schwarz Pharma as licensee of Warner Lambert. However, the Court of Appeals has remanded the case to the District Court for further proceedings, Teva said.

“Yesterday's ruling...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.